Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 in KRAS G12D mutant metastatic pancreatic cancer
NCT07026916Phase 2Withdrawn
- Sponsor
- GenFleet Therapeutics
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of GFH375 in pancreatic cancer (PC), sponsored by GenFleet Therapeutics. Planned start Aug 2025; status: withdrawn.
02
Drugs
GFH375
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07026916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026916.